0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Protein > FGF basic > GMP-FGCH17

GMP Human FGF basic Protein

Recommended Hot Products:
PG version BFF-H4117 is now available for seamless transition.

Order Now

  • Features
    1. Designed under ISO 9001:2015 and ISO 13485:2016

    2. Manufactured and QC tested under a GMP compliance factory

    3. Animal-Free materials

    4. Beta-lactam materials free

    5. Batch-to-batch consistency

    6. Stringent quality control tests

    7. No animal derived peptone and lactose used in production process

  • Source
    GMP Human FGF basic Protein(GMP-FGCH17) is expressed from E. coli cells. It contains AA Pro 143 - Ser 288 (Accession # P09038-4).
    Predicted N-terminus: Pro 143
  • Molecular Characterization
    FGF basic Structure

    This protein carries no "tag".

    The protein has a calculated MW of 16.5 kDa. The protein migrates as 17 kDa±3 kDa under reducing (R) condition (SDS-PAGE).

  • Endotoxin
    Less than 10 EU/mg by the LAL method.
  • Host Cell Protein
    <0.5 ng/µg of protein tested by ELISA.
  • Host Cell DNA
    <0.02 ng/μg of protein tested by qPCR.
  • Sterility
    The sterility testing was performed by membrane filtration method described in CP<1101>, USP<71> and Eur. Ph. 2.6.1.
  • Mycoplasma
    Negative.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with protectants.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with blue ice, please inquire the shipping cost.

  • Storage

    Upon receipt, store it immediately at -20°C or lower for long term storage.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 5 years in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
SDS-PAGE
FGF basic SDS-PAGE

GMP Human FGF basic Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-Bioactivity CELL BASE
 FGF basic CELL

GMP Human FGF basic Protein (Cat. No. GMP-FGCH17) stimulates proliferation of NIH/3T3 cells. The specific activity of GMP Human FGF basic Protein is >2.50 x 10^6 IU/mg, which is calibrated against Basic Fibroblast Growth Factor WHO International Standard (NIBSC code: 90/712) (QC tested).

 FGF basic CELL

The activity of GMP Human FGF basic Protein (Cat. No. GMP-FGCH17) was higher than other competing products.

Application Data
 FGF basic APPLICATION DATA

FGF basic (Cat. No. GMP-FGCH17) could highly support stemness maintenance in ESC/iPSC compared to other companies.

Left: The mRNA expression of pluripotent stem cell markers (Oct4, Nanog) was higher in Acro than in company R and company P.

Right: When FGF basic (35 μg/mL) is added into the culture media (StemSure hPSC medium) for iPSC, the cells remain high expression of pluripotent (Oct4+ or Nanog+; pink) markers.

 FGF basic APPLICATION DATA

GMP Human SCF Protein (Cat. No. GMP-SCFH25), GMP Human Thrombopoietin Protein (Cat. No. GMP-THNH25), GMP Human Flt-3 Ligand Protein (Cat. No. GMP-FLLH28), GMP Human FGF basic Protein (Cat. No. GMP-FGCH17) and GMP Human VEGF165 Protein (Cat. No. GMP-VE5H23) could significantly promote the iPSC differentiation to HSPCSs after 14 days, highly expressed hematopoietic stem cell markers CD34 and CD45.

 FGF basic APPLICATION DATA

GMP Human FGF basic Protein (Cat. No. GMP-FGCH17) and GMP Human TGF-Beta 1 Protein (Cat. No. GMP-TG1H25) could maintain the stemness of hiPSCs with high expression of stem cell genes OCT4, SOX2, and SSEA4 with GMP Human Laminin 521 Protein (Cat. No. GMP-LA5H24).

Bioactivity-Stability
 FGF basic STABILITY

The Cell based assay shows that GMP Human FGF basic Protein (Cat. No. GMP-FGCH17) is stable at 37°C for 24 hours.

 FGF basic STABILITY

The Cell based assay shows that GMP Human FGF basic Protein (Cat. No. GMP-FGCH17) is stable after freezing and thawing 3 times.

 FGF basic STABILITY

The Cell based assay shows that GMP Human FGF basic Protein (Cat. No. GMP-FGCH17 ) is stable at 4℃ for 30 days.

 FGF basic STABILITY

The Cell based assay shows batch-to-batch consistency between Acro's GMP and PG FGF basic.

  • MANUFACTURING SPECIFICATIONS

    ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP<92>Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP<1043>Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.


    ACROBiosystems Quality Management System Contents:

    1. Designed under ISO 9001:2015 and ISO 13485:2016, Manufactured and QC tested under a GMP compliance factory.

    2. Animal-Free materials

    3. Materials purchased from the approved suppliers by QA

    4. ISO 5 clean rooms and automatic filling equipment

    5. Qualified personnel

    6. Quality-related documents review and approve by QA

    7. Fully batch production and control records

    8. Equipment maintenance and calibration

    9. Validation of analytical procedures

    10. Stability studies conducted

    11. Comprehensive regulatory support files

    Request For Regulatory Support Files(RSF)


    ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

    1. SDS-PAGE

    2. Protein content

    3. Endotoxin level

    4. Residual Host Cell DNA content

    5. Residual Host Cell Protein content

    6. Biological activity analysis

    7. Microbial testing

    8. Mycoplasma testing

    9. In vitro virus assay

    10. Residual moisture
    11. Batch-to-batch consistency

  • Background
    FGF basic (also known as FGF2 and HBGF-2) is an 18-34 kDa, heparin-binding member of the FGF superfamily of molecules (1-3). Superfamily members are characterized by the presence of a centrally placed beta -trefoil structure. FGF acidic (FGF-1) and FGF basic (FGF2) were the first two identified FGFs, and the designations acidic and basic refer to their relative isoelectric points. Human FGF basic is 288 amino acids (aa) in length. There are multiple start sites, four of which utilize atypical CUG codons, and one that initiates at an AUG start site (4 - 6). The four CUG start sites generate high molecular weight (HMW) FGF basic. There is a 34 kDa, 288 aa form, a 24 kDa, 210 aa form, a 22.5 kDa, 201 aa form, and a 22 kDa, 196 aa form. All are retained intracellularly, undergo extensive methylation, and possess one or more nuclear localization signals (NLS) (7-9). The AUG initiating form is 18 kDa and 155 aa in length. There is no signal sequence (ss). It is, however, secreted directly through the plasma membrane via a mechanism that appears to be dependent upon tertiary structure (10). In place of a ss, there is purportedly a 9 aa N-terminal prosegment that precedes a 146 aa mature segment (11). Early isolations of 18 kDa bovine FGF basic yielded 146 aa molecules, an effect attributed to the presence of acid proteases (12). The molecule contains a heparin-binding site (aa residues 128-144), and undergoes phosphorylation at Ser117 (13). There is also an ill-defined C-terminal NLS that may be more “functional” (or 3-dimensional) than structural (7). Human 146 aa FGF basic is 97% aa identical to mouse FGF basic (14).
  • Clinical and Translational Updates

Comments (0)


Voraussichtlicher Liefertermin für vorrätige Produkte: 2 Arbeitstage

Price(EUR) : €380.00

Price(EUR) : €1700.00

Price(EUR) : €2270.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:3 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Nachricht schicken